Consensus Statement on Hemostatic Management, Anticoagulation, and Antiplatelet Therapy in Liver Transplantation.

Autores de IIS La Fe

• Eva María Montalvá Orón

  Autor

• Santiago Bonanad Boix

  Autor

Participantes ajenos a IIS La Fe

• Rodríguez-Perálvarez M
• Blasi A
• Gavín O
• Hierro L
• Lladó L
• Llop E
• Pozo-Laderas JC
• Colmenero J
• Spanish Society of Liver Transplantation and the Spanish Society of Thrombosis a

Grupos

• Hemostasia, Trombosis, Arteriosclerosis y Biología vascular

• Hepatología, Cirugia Hepatobiliopancreática y Trasplantes

Abstract

Anticoagulation and antiplatelet therapies are increasingly used in liver transplant (LT) candidates and recipients due to cardiovascular comorbidities, portal vein thrombosis, or to manage posttransplant complications. The implementation of the new direct-acting oral anticoagulants and the recently developed antiplatelet drugs is a great challenge for transplant teams worldwide, as their activity must be monitored and their complications managed, in the absence of robust scientific evidence. In this changing and clinically heterogeneous scenario, the Spanish Society of Liver Transplantation and the Spanish Society of Thrombosis and Haemostasis aimed to achieve consensus regarding the indications, drugs, dosing, and timing of anticoagulation and antiplatelet therapies initiated from the inclusion of the patient on the waiting list to post-LT surveillance. A multidisciplinary group of experts composed by transplant hepatologists, surgeons, hematologists, transplant-specialized anesthesiologists, and intensivists performed a comprehensive review of the literature and identified 21 clinically relevant questions using the patient-intervention-comparison-outcome format. A preliminary list of recommendations was drafted and further validated using a modified Delphi approach by a panel of 24 transplant delegates, each representing a LT institution in Spain. The present consensus statement contains the key recommendations together with the core supporting scientific evidence, which will provide guidance for improved and more homogeneous clinical decision making.

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Keywords

• PORTAL-VEIN THROMBOSIS; HEPATIC-ARTERY THROMBOSIS; TRANSCATHETER THROMBOLYTIC THERAPY; INTRAHEPATIC PORTOSYSTEMIC SHUNT; BLOOD-CELL TRANSFUSION; RISK-FACTOR; PERIOPERATIVE MANAGEMENT; VENOUS THROMBOEMBOLISM; REBALANCED HEMOSTASIS; EUROPEAN-SOCIETY